Oncogenic EP300 Can Be Targeted With Inhibitors of Aldo-Keto Reductases

Biochemical Pharmacology - Netherlands
doi 10.1016/j.bcp.2019.03.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Aldo-Keto Reductases 1B in Adrenal Cortex Physiology

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2016English

Regulation of Aldo–Keto Reductases in Human Diseases

Frontiers in Pharmacology
Pharmacology
2012English

The Diversity of Microbial Aldo/Keto Reductases From Escherichia Coli K12

Chemico-Biological Interactions
MedicineToxicology
2013English

Aldo-Keto Reductases and Formation of Polycyclic Aromatic Hydrocarbon O-Quinones

Methods in Enzymology
2004English

Aldo-Keto Reductases Protect Metastatic Melanoma From ER Stress-Independent Ferroptosis

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2019English

Age-Dependent Change in Aldo-Keto Reductases Composition in the Blood of Rats

American Journal of Biomedical and Life Sciences
2014English

Roles of Rat and Human Aldo–keto Reductases in Metabolism of Farnesol and Geranylgeraniol

Chemico-Biological Interactions
MedicineToxicology
2011English

Aldo-Keto Reductases Protect Lung Adenocarcinoma Cells From the Acute Toxicity of B[a]P-7,8-Trans-Dihydrodiol

Chemical Research in Toxicology
MedicineToxicology
2011English

N-Benzoyl Anthranilic Acid Derivatives as Selective Inhibitors of Aldo–keto Reductase AKR1C3

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy